The venture investment arm of a Large Pharmaceutical Company with offices throughout the United States and Europe is looking to invest in 5-10 firms over the course of the next year. The firm covers a broad range of investments from seed through Series A, B, and C rounds. The firm typically commits ~$25m over the life of an investment.
The firm invests in promising companies developing breakthrough innovations for high unmet need clinical problems. The firm broadly covers the healthcare market with investments across therapeutics, devices, diagnostics and healthcare services. The firm will consider opportunities ranging from discovery concept through Phase II. The fund is highly focused on technology innovation and will invest across all therapeutic areas and technology modalities.
The firm invests in pre-revenue, early stage companies, and prefers to invest in management teams with a foundation of expertise in their field. In cases where the firm invests at the seed stage, the fund may be a very hands-on investor to help build the company, but is typically less hands-on when investing in mature companies. As an early-stage investor the firm typically invests in privately-held companies, but also has the capability to invest in public companies and has had several portfolio companies go public subsequent to investment
Next Phase Newsletter 
Leave a comment